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The purpose of this study was to evaluate the diagnostic efﬁciency for hepatocellular carcinoma
(HCC) with the combined analysis of alpha-L-fucosidase (AFU), alpha-fetoprotein (AFP) and thymi-
dine kinase 1 (TK1). Serum levels of AFU, AFP and TK1 were measured in: 116 patients with HCC,
109 patients with benign hepatic diseases, and 104 normal subjects. The diagnostic value was
analyzed using the logistic regression equation and receiver operating characteristic curves (ROC).
Statistical distribution of the three tested tumor markers in every group was non-normally
distributed (Kolmogorov–Sminov test, Z = 0.156–0.517, P < 0.001). The serum levels of AFP and
TK1 in patients with HCC were signiﬁcantly higher than those in patients with benign hepatic dis-
eases (Mann–Whitney U test, Z = 8.570 to –5.943, all P < 0.001). However, there was no statistically
signiﬁcant difference of AFU between these two groups (Mann–Whitney U test, Z = 1.820,
P = 0.069). The levels of AFU were signiﬁcantly higher in patients with benign hepatic diseases than
in normal subjects (Mann–Whitney U test, Z = 7.984, P < 0.001). Receiver operating characteristic
curves (ROC) in patients with HCC versus those without HCC indicated the optimal cut-off value
was 40.80 U/L for AFU, 10.86 lg/L for AFP and 1.92 pmol/L for TK1, respectively. The area under
ROC curve (AUC) was 0.718 for AFU, 0.832 for AFP, 0.773 for TK1 and 0.900 for the combination of
the three tumor markers. The combination resulted in a higher Youden index and a sensitivity of
85.3%. The combined detection of serum AFU, AFP and TK1 could play a complementary role in
the diagnosis of HCC, and could signiﬁcantly improve the sensitivity for the diagnosis of HCC.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite progress made being during the past few decades, HCC
is still one of the most frequent and deadly cancers worldwide in
both men and women. In the United States, HCC ranks as having
the ﬁfth highest mortality in males, with an estimated 14,890
death cases and ranked ninth in females, with an estimated 6780
death cases, according to the 2013 report by the United Statescancer society [1]. Globally, there are approximately 750,000 new
cases of liver cancer reported each year, 70–85% of which are
HCC [2,3]. Due to the asymptomatic nature of an early case of
HCC and lack of effective diagnostic and screening strategies, most
patients (>80%) are presented with the apparent advanced stage of
HCC [4]. It is well known that the prognosis of HCC is poor.
Therefore, the prevention of HCC is a signiﬁcant public health
issue. Early detection for HCC is of the utmost importance [5].
Detection of a tumor biomarker is effective and a common
approach to screen HCC because it is convenient, non-invasive
and inexpensive with a high degree of accuracy.
Alpha-L-fucosidase (AFU) is a liposomal enzyme widely present
in all mammalian cells, blood and body ﬂuid. It can be found in the
serum of healthy adults. The activity of this liposomal enzyme is
detectable and elevated activities are observed in the sera of
HCC patients compared with chronic liver disease and healthy
individuals [6,7].
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liver and yolk sac during prenatal development. The fetal liver
becomes the main site of AFP synthesis as the yolk sac degenerates
after 12 weeks of gestation [8]. AFP levels are usually high at birth
and decrease to adult levels within the ﬁrst year of life. In healthy
pregnant women AFP may reach concentrations of 250 mg/L. After
birth, these concentrations fall rapidly [9]. AFP is widely used as a
tumor biomarker in the early diagnosis of HCC.
TK1 is a diagnostic biomarker for a variety of tumor types,
which is involved in DNA repair and is primarily elevated during
S phase. TK1 is associated with proliferating cells [10]. A clinical
investigation [11] performed on 11,880 people within China during
2005 to 2007 showed that serum level of TK1 with values
>2.0 pmol/L may indicate an early risk for the development of
malignancies later in life.
Today, lots of tumor biomarkers have been conducted as a com-
plement or substitute for AFP in order to improve sensitivity and
speciﬁcity in diagnosing HCC. The aim of the present study is to
assess the diagnostic value of joint detection of AFU, AFP and
TK1 in the diagnosis for HCC.Table 12. Material and methods
We retrospectively analyzed the clinic pathologic data of
patients with HCC and benign liver disorders at the Department
of Oncology in Afﬁliated Fuding Hospital, Fujian University of
Traditional Chinese Medicine in China between January 2012 and
November 2014. They included a group of 116 patients with HCC
and a group of 109 patients with benign liver diseases.
Additionally, a group of 104 healthy blood specimens from routine
check-ups within the same hospital were used as controls at the
same time. There were 75 males and 41 females with a mean
age of 57.8 ± 11.3 years (range, 27–79 years) in HCC group, 68
males and 41 females with a mean age of 54.1 ± 11.9 years (range,
32–84 years) in benign liver disease group and 70 males and 34
females with a mean age of 56.9 ± 16.0 years (range, 22–85 years)
in normal control group, respectively.
Diagnosis for HCC was based on clinical investigations, which
included laboratory tests, along with radiological imaging in
selected cases. After hepatic resection, two pathologists conﬁrmed
the diagnosis of HCC conducted histopathological examination of
the tissue specimens. Diagnosis of benign liver disease was based
on liver histology as well as laboratory and imaging evidence of
hepatic decomposition or portal hypertension. The benign liver
disease included liver cirrhosis and chronic hepatitis. None of
104 healthy control subjects were positive for the biomarkers of
hepatitis viruses A, B, C, D, and E; HIV antibodies; or had liver; gall-
bladder; or kidney disease.
All blood samples were collected from subjects before treat-
ment. The local Ethics Committees approved this study.Clinical parameters of HCC group, benign liver disease group and normal control
group [case (%)].
Items HCC group
(n = 116)
Benign disease
group (n = 109)
Normal
group (104)
F/v2 P
value
Mean age
(year)
57.8 ± 11.3 54.1 ± 11.9 56.9 ± 16.0 2.431 0.090
Gender 0.173 0.917
Male 75 (63.0) 72 (67.9) 70 (67.3)
Female 41 (37.0) 37 (32.1) 34 (32.7)
Etiology 0.551 0.458*
HBV 90 (77.6) 83 (76.1)
HCV 18 (15.5) 21 (19.3)
Others# 8 (6.9) 5 (4.6)
* HCV versus HBV and others.
# Including HAV, HDV, HEV and HIV.2.1. Methods
Peripheral blood samples were extracted from cases and con-
trols prior to treatment. Fresh serum samples were shipped to clot
for a period of thirty minutes at 37 C. Samples were then sepa-
rated by 3000 RPM centrifugal 10 min. The supernatant sera were
collected and stored at 20 C until testing. Although, AFU activity
was assayed within 30 days after collection [12]. The serum AFU
activities were assayed using a biochemistry analyzer. The serum
levels of AFP were assayed by an electrochemiluminescence
analyzer Eleusis 2010 with supporting reagents (Roche, German).
The concentrations of TK1 were measured by using a commercialKit based on an enhanced chemiluminescent (ECL) dot blot assay
in accordance with instructions by the manufacturer (SSTK Ltd.,
Shenzhen, China). Normal reference values of AFU, AFP and TK1
were <40.0 U/L, <10.0 lg/L and <2.0 pmol/L, respectively.
2.2. Statistical analysis
Statistical analysis was performed using the SPSS 22.0 software
package. Markers concentration distribution of patients in HCC,
benign liver disorder and normal control groups were carried out
by means of Kolmogorov–Sminov test, calculating the tumor
marker concentration and Median (P25 and P75).
Kruskal–Wallis and Chi-square tests were conducted for a
comparison of tumor marker concentration levels among the
different groups of subjects included. Comparison of continuous
variables between the two groups was performed using the
Mann–Whitney U-test. The receiver operating characteristics
(ROC) curves, which correlated true-positive and false-positive
rates (sensitivity and 1-speciﬁcity), were displayed. The areas
under the ROC curve (AUC) were calculated for each biomarker
as well. The statistical signiﬁcance of differences after logistic
regression between the two AUCs was also determined.
Statistical analysis was conducted by logistic regression, analyzing
diagnosis value of single and combined detection of the three
tested tumor markers for HCC. The ROC curve was displayed with
SPSS 22.0. In all tests, statistical signiﬁcance was considered at P
value less than 0.05.
3. Results
3.1. Study population
The present study was performed on a total of 225 patients with
different liver diseases and 104 healthy subjects. Table 1 shows the
major attributes of the subjects enrolled.
3.2. Tumor markers Kolmogorov–Sminov test
Statistical distribution of the three tested tumor markers in
every group was Kolmogorov–Sminov test with Z = 0.156–0.517,
P < 0.001, which was non-normally distributed, and non-parametric
tests were used in the following statistical analysis.
3.3. Tumor marker concentrations in cases and controls
The concentrations of AFU, AFP and TK1 were statistically
different among the three groups (v2 = 70.311–104.425, all
P < 0.001). AFP and TK1 levels were higher in HCC group than those
in benign liver disorder group with the exception of AFU; AFU
Table 2
The mean concentrations of AFU, AFP and TK1 in cases and controls [Median (P25–P75)].
Group n AFU (U/L) AFP (lg/L) TK1 (pmol/L)
HCC 116 51.0 (37.5–79.2) 306.0 (9.7–3020.0) 2.34 (1.4–4.1)
Benign liver disorder 109 46.1 (35.9–67.2) 5.1 (2.6–8.1) 1.3 (0.8–2.0)
Control 104 28.0 (25.0–34.0) 6.0 (4.0–8.0) 1.3 (1.0–1.6)
Kruskal–Wallis test was carried out among the three groups with three tumor markers: v2 = 70.311–104.425, all P < 0.001. Mann–Whitney U test was carried out between the
following two groups: (1), HCC group versus benign liver disease group: AFU (Z = 1.820, P = 0.069), AFP (Z = 8.570, P < 0.001), TK1 (Z = 5.943, P < 0.001); (2), benign liver
disease group versus control group: AFU (Z = 7.984, P < 0.001), AFP (Z = 0.527, P = 0.598), TK1 (Z = 1.575, P = 0.115).
Table 3
Positive rates of AFU, AFP and TK1 in each group [case (%)].
Groups Case (n) AFU [n(%)] AFP [n(%)] TK1 [n(%)]
HCC 116 84 (70.6) 87 (73.1) 67 (56.3)
Benign disorder 109 72 (67.9) 22 (20.8) 29 (27.4)
Healthy control 104 8 (7.7) 0 (0.0) 2 (1.9)
Chi-square test or Fischer’s exact test was performed when appropriate. HCC group
versus benign disorder group: AFU (v2 = 6.270, P = 0.012), AFP (v2 = 18.538,
P < 0.001), and TK1 (v2 = 13.115, P = 0.003); benign liver disorder group versus
control group: AFU (v2 = 28.586, P < 0.001), AFP (v2 = 16.958, P < 0.001), and TK1
(v2 = 4.449, P < 0.001).
Fig. 1. ROC curve comparing AFU, AFP and TK1 levels in patients with HCC versus
patients without HCC (including patients with benign disease and normal subjects).
The curves show optimal cut-off value for AFU of 40.80 U/L, for AFP of 10.86 lg/L
and for TK1 of 1.92 pmol/L. The area under the ROC curve was 0.718 for AFU, 0.832
for AFP, 0.773 for TK1 and 0.900 for the combination of AFU, AFP and TK1.
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control group, except AFP and TK1 (Table 2).
3.4. The positive rate of tumor markers in all groups
According to the reference values, the three tested tumor
markers in patients with HCC were statistically different compared
with those in benign liver disease group and control group
(P < 0.001, Table 3).
3.5. Logistic regression and ROC curve in HCC group versus non-HCC
group
The receiver operating characteristic curve (ROC) for analysis of
single AFU, AFP, TK1 and the combination in patients with HCC in
comparison with patients without HCC were plotted. The areas
under the curves of the three tested tumor markers were: AFU:
0.718 (95% CI: 0.662–0.774, P < 0.001); AFP: 0.832 (95% CI:
0.778–0.887, P < 0.001); TK1: 0.773 (95% CI: 0.719–0.823,
P < 0.001); the combination: 0.900 (95% CI: 0.863–0.937). Logistic
regression was used of calculating the logistic regression equation
of the serum concentrations of APU, AFP and TK1. Logit
(P) = 3.331 + 0.013  AFU + 0.05  AFP + 0.680  TK1. The model
was founded with logistic regression, and the ROC curve was ﬁtted
through the PRE of the model (Fig. 1). Among the AUCs of the three
tumor markers with predicted probability connected with single
tumor marker and logistic regression curve, when three tumor
markers were tested separately, the AUC of AFP was the highest,
followed by that of TK1, and the AUC of AFU was the lowest. Yet,
the three tumor markers combined in the logistic regression model
was higher than that of every tumor marker tested separately.
3.6. Tumor marker evaluation parameters
Sensitivity, speciﬁcity, Youden’s index (sensitivity + speci-
ﬁcity  1) and diagnostic accuracy (Table 4) of AFU, AFP and TK1
were calculated according to the ROC curves and the logistic
regression. Conjoint analysis: regarding AFP as the basic indicator,
on the basis of which the indicators of AFU, AFP and TK1 were
analyzed jointly. The sensitivity of the combination of the rest
indicators was increased while the rest indicators, such as
speciﬁcity and so on, were decreased evidently.4. Discussion
The serum level of AFP has been commonly used as a traditional
method for early diagnosis of HCC in China [13]. Be that as that
may, an elevated AFP level is also obtained in certain benign liver
disorders, such as viral hepatitis, liver cirrhosis and exacerbations
of chronic hepatitis, and other cancers, which are the most preva-
lent cancers of the digestive tract (pancreas  24%, stomach  15%,
large intestine  3%, and gallbladder) [14,15]. Moreover, false-
negative or false–positive results can often be detected for some
reason – including geographical and ethnic variations and different
techniques being performed [7]. For these reason, it is necessary to
perform a conjoint combination of various of biomarkers in the
diagnosis of HCC [7].
The present study shows that the concentration of AFP is signiﬁ-
cantly higher in patients with HCC than patients with benign liver
diseases and control subjects, a ﬁnding that came in agreement
with the work of El-Tayeh et al. [16]. The ROC curve comparing
HCC versus non-HCC shows its sensitivity of 75.0%, high speciﬁcity
of 92.0% and diagnostic accuracy of 85.9% at the optimal cut-off of
10.86 lg/L. This means that 25% of the studied patients with HCC
are negative for AFP. The result is similar to the study by
Marrero et al. [17], which showed that AFP at a cutoff of 10.9 lg/
L is currently the best serum biomarker for the diagnosis of early
stage HCC.
AFU is also a useful biomarker of the diagnosis for HCC. AFU has
been recommended as a serum biomarker for HCC in some studies.
In the present study, the sensitivity of AFU was 72.4% and the
speciﬁcity was 63.8%. Our ﬁnding came in agreement with a
Table 4
The diagnosis efﬁciency of the conjoint analysis of tumor markers (HCC group versus non-HCC group).
Items AFU AFP TK1 Combination
Optimal cut-off 40.80 U/L 10.86 lg/L 1.92 pmol/L –
Sensitivity (%) 72.4 75.0 63.8 85.3
Speciﬁcity (%) 63.8 92.0 83.1 83.1
Diagnostic accuracy (%) 66.9 85.9 76.1 83.9
Younden’s index (%) 36.2 67.0 46.9 68.4
SE 0.029 0.028 0.028 0.019
AUC (95% CI) 0.718 (0.662–0.774) 0.832 (0.778–0.887) 0.773 (0.719–0.827) 0.900 (0.863–0.937)
Z-value# 5.379 2.010 3.753 –
P-value# <0.01 <0.05 <0.01 –
# Comparing the area under ROC curve of combination to single tumor marker in HCC versus non-HCC. SE, standard error. AUC, area under the receiver operating
characteristic.
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[18], which showed that the pooled sensitivity of AFU for HCC
was 0.72 [95% conﬁdence interval (CI):0.69–0.76], while the pooled
speciﬁcity was 0.78 (95% CI: 0.74–0.81). Moreover, AFU in the cur-
rent study recorded an AUC of 0.718 indicating its validity as a
diagnostic biomarker of HCC. Therefore, AFU activity may be
regarded as a valuable biomarker for the diagnosis of HCC.
Some clinical investigation [19] showed that elevated TK1 val-
ues indicated active tumor growth. Serological TK1 could be a use-
ful marker for an early risk of development of any type of
malignancy [20]. In the current study, the serum TK1 was dramati-
cally elevated in patients with HCC comparing to patients with
benign liver diseases and healthy subjects, which came in agree-
ment with the study by Zhi et al. [11]. The latter study [11] showed
a sensitivity of 85.7% and a speciﬁcity of 99.7% in the diagnosis of
liver tumor versus normal control, whereas our present investiga-
tion had a sensitivity of 63.8% and a speciﬁcity of 83.1% in the
diagnosis of liver tumor in comparison with benign liver diseases
and normal subjects.
The serum tumor markers are widely used for diagnosis of HCC.
Of all the serum tumor markers, AFP is the most commonly one
and serve as an important tool in the monitoring of HCC patients
[21]. However, the low sensitivity and speciﬁcity of AFP for HCC
limits its clinical application. Consequently, in order to improve
the diagnostic performance for HCC, the combination of AFP with
other serum tumor markers is recommended in the diagnosis of
HCC [2,22,23]. Previous studies have proven that a combination
of serum tumor markers had a better diagnostic performance for
HCC [2,22–25]. The results of these studies were in agreement with
the current study concerning the combination of tumor markers
for diagnosis of HCC. The simultaneous determination of the tested
tumor markers (AFU, AFP and TK1) showed the largest AUC [0.900
(95% CI: 0.863–0.937)] and increased the sensitivity gradually up
to 85.3%. The simultaneous sensitivity of 85.3% was highest in
the three tumor markers. This suggests that several markers
should be conducted in order to obtain a reliable detection of
HCC [23].
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